Antitumor cytotoxicity mediated by ligand-activated human Vα24 NKT cells
T Kawano, T Nakayama, N Kamada, Y Kaneko… - Cancer research, 1999 - AACR
T Kawano, T Nakayama, N Kamada, Y Kaneko, M Harada, N Ogura, Y Akutsu, S Motohashi…
Cancer research, 1999•AACRHuman Vα24 NKT cells bearing an invariant Vα24JαQ antigen receptor, the counterpart of
the murine Vα14 NKT cells, are activated by the specific ligand, α-galactosylceramide (α-
GalCer) in a CD1d-dependent manner. Here, we demonstrate that the α-GalCer-activated
Vα24 NKT cells exert a potent perforin-dependent cytotoxic activity against a wide variety of
human tumor cell lines. In addition, we demonstrate that Vα24 NKT cells and dendritic cells
(DCs) from melanoma patients are functionally normal, even in the tumor-bearing status …
the murine Vα14 NKT cells, are activated by the specific ligand, α-galactosylceramide (α-
GalCer) in a CD1d-dependent manner. Here, we demonstrate that the α-GalCer-activated
Vα24 NKT cells exert a potent perforin-dependent cytotoxic activity against a wide variety of
human tumor cell lines. In addition, we demonstrate that Vα24 NKT cells and dendritic cells
(DCs) from melanoma patients are functionally normal, even in the tumor-bearing status …
Abstract
Human Vα24 NKT cells bearing an invariant Vα24JαQ antigen receptor, the counterpart of the murine Vα14 NKT cells, are activated by the specific ligand, α-galactosylceramide (α-GalCer) in a CD1d-dependent manner. Here, we demonstrate that the α-GalCer-activated Vα24 NKT cells exert a potent perforin-dependent cytotoxic activity against a wide variety of human tumor cell lines. In addition, we demonstrate that Vα24 NKT cells and dendritic cells (DCs) from melanoma patients are functionally normal, even in the tumor-bearing status. The potential use of α-GalCer-activated Vα24 NKT cells and/or DCs from patients for cancer immunotherapy is discussed.
AACR